
Apexigen (APGN) via Brookline Capital Acq (BCAC) deck
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents.
This post is for subscribers only
SubscribeAlready have an account? Log in